Dr. Brian R. Webster, M.D.
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- University of North Carolina at Chapel Hill School of Medicine (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 953
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: University of North Carolina at Chapel Hill School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
NC license 102893
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Novant Health New Hanover Regional Medical Center Wilmington, NC
- Pender Memorial Hospital Burgaw, NC
Medical groups
- Wilmington Health PLLC (369 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 953
- Services billed
- 7,971
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 720 | 375 |
| Insertion of needle into vein for collection of blood sample | 706 | 381 |
| Blood test, comprehensive group of blood chemicals | 530 | 356 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 443 | 300 |
| Dxa bone density measurement of hip, pelvis, spine | 397 | 397 |
| Hemoglobin a1c level | 347 | 220 |
| Blood test, lipids (cholesterol and triglycerides) | 302 | 259 |
| Urine microalbumin (protein) level | 130 | 104 |
| Creatinine level to test for kidney function or muscle injury | 130 | 104 |
| Administration of influenza virus vaccine | 96 | 95 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $1,179,650 in research payments for these studies, mostly to the institutions running them.
- Roche Cancer Screening Collection Study
Genentech, Inc. - A phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd …
AstraZeneca Pharmaceuticals LP - A phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outco…
AstraZeneca Pharmaceuticals LP - A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
Eli Lilly and Company · Recruiting · NCT06566170 - A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM
Alnylam Pharmaceuticals Inc. - A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease an…
AstraZeneca Pharmaceuticals LP - A phase iii, randomized, controlled, observer-blind study to evaluate
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.